Tectonic Therapeutic Inc expected to post a loss of $1.35 a share - Earnings Preview
Tectonic Therapeutic Inc expected to post a loss of $1.35 a share - Earnings Preview
Tectonic Therapeutic Inc TECX.OQ TECX.O is expected to show no change in quarterly revenue when it reports results on August 5 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Tectonic Therapeutic Inc is for a loss of $1.35 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Tectonic Therapeutic Inc is $80.00, about 185.4% above its last closing price of $28.03
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -1.18 | -1.18 | -1.34 | Missed | -13.3 |
Dec. 31 2026 | -1.12 | -1.10 | -1.03 | Beat | 6.7 |
Sep. 30 2025 | -1.04 | -1.05 | -1.02 | Beat | 2.6 |
Jun. 30 2025 | -0.96 | -0.98 | -1.07 | Missed | -9 |
Mar. 31 2025 | -1.09 | -1.09 | -0.93 | Beat | 14.9 |
Dec. 31 2024 | -1.39 | -0.84 | Beat | 39.4 | |
Sep. 30 2024 | -0.82 | -0.82 | -1.20 | Missed | -45.5 |
Jun. 30 2024 | -1.40 | -1.50 | -4.34 | Missed | -189.3 |
This summary was machine generated August 3 at 11:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Tectonic Therapeutic
See all newsTectonic Therapeutic Inc reports results for the quarter ended June 30 - Earnings Summary
Tectonic Therapeutic Q2 net loss widens on higher costs
Tectonic Therapeutic Inc expected to post a loss of $1.35 a share - Earnings Preview
Brief: Tectonic Therapeutic Completes Enrollment In Tx45 Apex Phase 2 Clinical Trial In Ph-Hfpef Patients
Tectonic Therapeutic Q1 net loss widens on higher R&D costs